<DOC>
	<DOC>NCT01582698</DOC>
	<brief_summary>The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.</brief_summary>
	<brief_title>TBE Seropersistence up to 10 Years After First Booster in Adults</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Tick-Borne</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects who participated in the first and second precursor studies will be eligible for participation in this study if: they understand the nature of the study, agree to its provisions and provide written informed consent they received the first booster vaccination with FSMEIMMUN 0.5ml during the first precursor study and did not receive a second booster vaccination in the second precursor study blood was drawn after their first booster vaccination in the first precursor study Subjects will be excluded from participation in this study if they: received any TBE vaccination since their first booster vaccination with FSMEIMMUN 0.5ml have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese Bencephalitis) since their first booster vaccination with FSMEIMMUN 0.5ml are known to be HIV positive since their first booster vaccination with FSMEIMMUN 0.5ml have a known or suspected problem with drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>